Completed or ongoing clinical trials for inhibitors of the PI3K/AKT/mTOR pathway according to highest phase reached for trials including ovarian cancer patients, indication, monotherapy or combination therapy, clinical trials and publication references. The gene discussed is PIK3CD; the disease is ovarian carcinoma.